Outcome of Board Meeting of Piramal Pharma Limited held on 27th October, 2026

Piramal Pharma Limited 27th October, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Outcome of Board Meeting of Piramal Pharma Limited (‘Company’) held on 27th October, 2026 Dear Sir / Madam, Kindly refer to our letter dated 16th October, 2026 on the subject. Pursuant to the provisions of Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), the Board of Directors of the Company at its meeting held today, i.e. 27th October, 2026, has inter alia, approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2026. In this regard, please find enclosed the following: a. Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September, 2026; b. Limited Review Reports by the Statutory Auditors. Further, we are arranging to publish the above-mentioned financial results in newspapers as per Regulation 47 of the SEBI Listing Regulations. The above information is also available on the website of the Company at www.piramalpharma.com. The meeting of the Board of Directors commenced at 5:30 pm and concluded at 8:30 pm. You are requested to take the above information on record. Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Encl.: a/a Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com Piramal Pharma Limited PIRAMAL PHARMA LIMITED Ananta Building, Plramal Corporate Park, Opposite Fire Brigade, Kamanl Junction, LBS Marg, Kurla (West), Mumbai - 400 070 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2026 /Rs in Croresl Year to date figures Year to date figures Corresponding Three Three months ended Three months ended for the current period for the previous period For the year ended Particulars September 30, 2026 June 30, 2026 months ended ended September 30, ended September 30, March 31, 2026 September 30, 2025 2026 2025 IUnauditedl IUnauditedl IUnauditedl IUnauditedl IUnauditedl IAuditedl Revenue from operations 1,345.38 1,124.95 1,127.26 2,470.33 2,097.14 4,782.01 other income (Net) 137.93 114.63 201.97 252.56 382.89 662.73 Total Income 1,483.31 1,239.58 1,329.23 2,722.89 2,480.03 5,444.74 Expenses Cost of materials consumed 353.51 649.70 350.95 1,003.21 760.71 1,342.70 Purchases of stock-in-trade 245.30 234.64 215.85 479.94 408.12 866.18 Changes in inventories of finished goods, work-in-progress and stock-in-trade 5.93 (390.29) (110.17) (384.36) (286.04) (138.98) Employee benefits expense 218.16 216.34 188.52 434.50 390.47 744.82 Finance costs 17.27 16.36 20.38 33.63 43.61 79.95 Depreciation & amortisation expense and impairment charge 67.56 65.73 61.25 133.29 120.69 255.50 other expenses (Net) 350.98 297.62 355.04 648.60 652.48 1,325.29 Total Expenses 1,258.71 1,090.10 1,081.82 2,348.81 2,090.04 4,475.46 Profit before exceptional items and tax 224.60 149.48 247.41 374.08 389.99 969.28 Exceptional items (Refer Note 5) - - - - - (92.51) Profit before tax 224.60 149.48 247.41 374.08 389.99 876.77 Tax Expense Current tax (including prior year taxes) 39.33 24.93 32.55 64.26 52.18 114.68 Deferred tax (Net) 14.53 11.07 18.53 25.60 28.34 62.08 Total tax expenses 53.86 36.00 51.08 89.86 80.52 176.76 Net Profit after tax 170.74 113.48 196.33 284.22 309.47 700.01 other Comprehensive Income / (Loss) (OCI), net of tax expense A. Items that will not be reclassified to profit or loss Remeasurement of post employment benefit plans (4.41) (9.76) 0.14 (14.18) (4.73) (12.50) Income tax impact on above 1.11 2.46 (0.04) 3.57 1.19 3.15 B. Items that will be subsequently reclassified to profit or loss Deferred gains/(loss) on cash flow hedge 1.86 3.07 (36.79) 4.94 (35.55) (35.25) Income tax impact on above (0.47) (0.77) 9.26 (1.24) 8.95 8.87 Total other Comprehensive Income/(Loss), net of tax (1.91) (5.00) (27.43) (6.91) (30.14) (35.73) expense Total Comprehensive Income for the period 168.83 108.48 168.90 277.31 279.33 664.28 Paid-up Equity Share Capital (Face Value of Rs. 10/-each) 1,328.39 1,327.35 1,325.52 1,328.39 1,325.52 1,327.16 other Equity 6,813.97 Earnings Per Equity Share (EPS) (Face Value of Rs. 10/-each) (restated, not annualised for the quarters) a) Basic EPS for the period/year (Rs.) 1.29 0.85 1.48 2.14 2.34 5.28 b) Diluted EPS for the period/year (Rs.) 1.28 0.85 1.47 2.13 2.32 5.25 See accompanying notes to the unaudited standalone financial results Pinmal P~rma. Limited . CIN: L24297MH2020PLC-33859.2 Registe11ed Offi.ce1 -~B uild.mg, Pir.amal Corporate Park,. Qpip. Fir;i, Brigade, K.amam Junctio~ LB-S Marg, Kmfa. ~Vesl), Mmnbai- 400070, 1'>.~.a, fudi-a TelNo, +912'2 3802 :3000 J 40,00;':Emailldi shareholdeI$:pp~iramalcom -""1.11.~caln Piramal Pharma Limited Notes: 1 Statement of unaudited Standalone Assets and Liabilities : (Rs.in Crores) Particulars Asat Seotember 30 2026 March 31 2026 (Unaudited) (Audited) ASSETS 1. Non-Current Assets (a) Property, Plant & Equipment 1,984.75 2,021.50 (b) Capital Work in Progress 147.78 101.51 (c) Goodwill 160.55 160.55 (d) Intangible Assets 742.30 687.36 (e) Intangible Assets under development 56.37 119.60 (f) Right-of-use assets 192. 71 166.45 (g) Financial Assets: (i) Investments 3,641.24 3,486.05 (ii) Loans 609.69 511.54 (iii) Other Financial Assets 35.79 35.40 (h) Income Tax Assets (Net) 3.64 26.41 (i) Other Non-Current Assets 47.14 38.80 Total Non-Current Assets 7,621.96 7,355.17 2. Current Assets (a) Inventories 2,051.07 1,873.39 (b) Financial Assets: (i) Investments 79.61 93.55 (ii) Trade Receivables 1,313.58 1,405.84 (iii) Cash & Cash equivalents 360.48 559.03 (iv) Bank balances other than (iii) above 15.11 15.29 (v) Loans 24.94 22.73 (vi) Other Financial Assets 66.28 56.07 (c) Other Current Assets 643.40 372.20 Total Current Assets 4,554.47 4,398.10 Total Assets 12,176.43 11,753.27 EQUITY AND LIABILITIES 1. Equity (a) Equity Share capital 1,328.39 1,327.16 (b) Other Equity 7,122.53 6,813.97 Total Equity 8,450.92 8,141,13 2. Liabilities Non-Current Liabilities (a) Financial Liabilities: (i) Borrowings 237.88 420.86 (ii) Lease liabilities 85.85 61.35 (b) Provisions 115.87 94.31 (c) Deferred Tax Liabilities (Net) 288.98 269.34 Total Non-Current Liabilities 728.58 845.86 Current Liabilities (a) Financial Liabilities: (i) Borrowings 210.61 289.03 (ii) Lease liabilities 19.79 15.01 (iii) Trade Payables (a) Total outstanding dues of Micro enterprises and small enterprises 50.65 101.59 (b) Total outstanding dues of creditors other than Micro enterprises 2,128.85 1,909.86 and small enterprises (iv) Other Financial Liabilities 108.56 100.06 2,518.46 2,415.55 (b) Other Current Liabilities 427.50 304.65 (c) Provisions 48.85 42.21 (d) Current Tax Liabilities (Net) 2.12 3.87 Total Current Liabilities 2,996.93 2,766.28 Total Equity & Liabilities 12,176.43 11,753.27 Pir:unal Pharma Limited CTN: L24297MH2020PLC33S592 R,gistered Olli«: Alianta Building, Pu:amal Corpor.de Park, Opp. Fire Bri;;ade, Kam.ni Junction, LB6 Marg, Kw-la (West), Mumbai -400070, lvfahamhlra., India Tel No. +91 22 3S02300014000; Email Id: shareholder,.ppl1(>piramaloom l\V.01'-pu:il!D>ii!lplnI1Tli1 c:mn Piramal Pharma Limited 2 Statement of Standalone Cashflows for the six months ended September 30,2026 : For the For the Period ended Period ended Sep 30, 2026 Sep 30, 2025 (Unaudited) (Unaudited) Rs. in Crores Rs. in Crores A. CASH FLOW FROM OPERATING ACTIVITIES Profit before tax 374.08 389.99 Adjust [Showing first 8,000 characters — download PDF for full document]